The drug-naïve OCD patients imaging genetics, cognitive and treatment response study: methods and sample description.
OBJECTIVE
To describe a protocol that was based on an integrative neurobiological model of scientific investigation to better understand the pathophysiology of obsessive-compulsive disorder and to present the clinical and demographic characteristics of the sample.


METHODS
A standardized research protocol that combines different methods of investigation (genetics, neuropsychology, morphometric magnetic resonance imaging and molecular neuroimaging of the dopamine transporter) obtained before and after treatment of drug-naïve adult obsessive-compulsive disorder patients submitted to a sequentially allocated 12-week clinical trial with a selective serotonin reuptake inhibitor (fluoxetine) and group cognitive-behavioral therapy.


RESULTS
Fifty-two treatment-naïve obsessive-compulsive disorder patients entered the clinical trial (27 received fluoxetine and 25 received group cognitive-behavioral therapy). At baseline, 47 blood samples for genetic studies, 50 neuropsychological evaluations, 50 morphometrical magnetic resonance images and 48 TRODAT-1 single-photon emission computed tomography (SPECT) exams were obtained. After 12 weeks, 38 patients completed the protocol (fluoxetine = 20 and GCBT = 18). Thirty-eight neuropsychological evaluations, 31 morphometrical magnetic resonance images and 34 TRODAT-1 SPECT exams were obtained post-treatment. Forty-one healthy controls matched for age, gender, socioeconomic status, level of education and laterality were submitted to the same research procedures at baseline.


CONCLUSIONS
The comprehensive treatment response protocol applied in this project allowing integration on genetic, neuropsychological, morphometrical and molecular imaging of the dopamine transporter data in drug-naïve patients has the potential to generate important original information on the neurobiology of obsessive-compulsive disorder, and at the same time be clinically meaningful.
Hoexter
Marcelo Queiroz
MQ
Department & Institute of Psychiatry, Clinical Hospital, Medical School, Universidade de São Paulo, São Paulo, SP, Brazil. mqhoexter@gmail.com
Shavitt
Roseli Gedanke
RG
D'Alcante
Carina Chaubet
CC
Cecconi
Janaina Philippi
JP
Diniz
Juliana Belo
JB
Belotto-Silva
Cristina
C
Hounie
Ana Gabriela
AG
Borcato
Sonia
S
Moraes
Ivanil
I
Joaquim
Marines Alves
MA
Cappi
Carolina
C
Sampaio
Aline Santos
AS
Mathis
Maria Alice de
MA
Batistuzzo
Marcelo Camargo
MC
Lopes
Antonio Carlos
AC
Rosa
Ana Carolina Ferreira
AC
Muniz
Renan Kawano
RK
Marques
Andrea Horvath
AH
Santos
Luciana Cristina
LC
Taub
Anita
A
Duran
Fábio Luís de Souza
FL
Dougherty
Darin Dean
DD
Busatto
Geraldo Filho
GF
Bressan
Rodrigo Affonseca
RA
Miguel
Euripedes Constantino
EC
D000293:Adolescent; D000328:Adult; D000368:Aged; D015928:Cognitive Behavioral Therapy; D005473:Fluoxetine / Q000627:therapeutic use*; D006801:Humans; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D057054:Molecular Imaging; D009771:Obsessive-Compulsive Disorder / Q000503:physiopathology / Q000628:therapy*; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D015899:Tomography, Emission-Computed, Single-Photon; D016896:Treatment Outcome; D055815:Young Adult
D005473:Fluoxetine; D017367:Selective Serotonin Reuptake Inhibitors